Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

667
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
667

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Donor-Related Factors Affecting Haploidentical HSCT Outcomes in Acute Leukemia: A Single-Center Retrospective Cohort Study of a Modified Combination of Anti-Thymocyte Globulin and Post-Transplant Cyclophosphamide.

Health science reports·2026
Same author

Establishment of Integrated Hospital-Based Supportive and Palliative Services: An Experience from Iran.

International journal of hematology-oncology and stem cell research·2026
Same author

Ex vivo evaluation of Newcastle disease virus to enhance natural killer cell function against acute myeloid leukemia cells.

Scientific reports·2026
Same author

Harnessing CAR-NK cells against multiple myeloma: current landscape and future directions.

Molecular biology reports·2026
Same author

Predictive factors for poor mobilization in autologous stem cell transplant: a multivariate model.

Hematology, transfusion and cell therapy·2026
Same author

MR-AIV reveals in vivo brain-wide fluid flow with physics-informed AI.

Science advances·2026
Same journal

TLR7/8 agonist 3M-052 formulated in micelles induces local type I IFN response and antiviral immunity in zebrafish larvae.

Frontiers in immunology·2026
Same journal

HLA-DRB1*15:01 drives sex- and age-dependent microglial immune phenotypes and neuroimmune signaling.

Frontiers in immunology·2026
Same journal

Gut microbiota transfer from autoimmune dry eye mice imprints stereotypic B cell receptor repertoires in the lacrimal gland and induces disease.

Frontiers in immunology·2026
Same journal

Exosomal microRNAs in colorectal cancer communication networks: implications for metastasis, therapy resistance, and precision medicine.

Frontiers in immunology·2026
Same journal

TMEM160 promotes hepatocellular carcinoma cell proliferation, invasion, and immune evasion by regulating the VEGFA/PI3K/AKT signaling axis.

Frontiers in immunology·2026
Same journal

Nurr1 deficiency orchestrates a coupled liver-gut pathological axis revealed by multi-omics and deep-learning histopathology.

Frontiers in immunology·2026
See all related articles

Related Experiment Video

Updated: Sep 18, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.5K

Allogeneic CART progress: platforms, current progress and limitations.

Ameneh Shokati1, Maryam Sanjari-Pour2, Mahshid Akhavan Rahnama3

  • 1Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Frontiers in Immunology
|June 27, 2025
PubMed
Summary
This summary is machine-generated.

Allogenic CAR-T cells offer advantages over autologous therapies, with new technologies improving universal off-the-shelf options. These advancements address challenges like graft-versus-host disease for future cancer treatments.

Keywords:
allogeneic CAR T cellsediting technologygraft-versus-host diseasenon-editing technologyoff-the-shelf CART cell

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.3K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

811

Related Experiment Videos

Last Updated: Sep 18, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.5K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.3K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

811

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Allogenic chimeric antigen receptor T (CAR-T) cells present distinct advantages over autologous T cell therapies.
  • These benefits include improved cell availability, reduced risks from transduction methods, and avoidance of graft-versus-host disease (GVHD) and rejection when using HLA-matched donors.
  • Recent technological advancements, including gene editing and non-editing strategies, are pivotal in realizing the potential of allogenic CAR-T therapies.

Purpose of the Study:

  • To review recent advancements in allogenic CAR-T cell development and clinical applications.
  • To highlight the successes of universal off-the-shelf CAR-T cells in overcoming key challenges.
  • To summarize pre-clinical and clinical study outcomes over the past decade for hematological malignancies and cancers.

Main Methods:

  • Review of recent scientific literature and clinical trial data.
  • Analysis of engineering strategies for allogenic CAR-T cells.
  • Evaluation of clinical practices and outcomes in treating hematological malignancies and cancers.

Main Results:

  • Engineering and technological improvements are making allogenic CAR-T therapies more viable.
  • Universal off-the-shelf CAR-T cells are showing promise in addressing GVHD and production time constraints.
  • Significant successes have been observed in recent clinical studies utilizing allogenic CAR-T cells for hematological malignancies and cancers.

Conclusions:

  • Allogenic CAR-T cell therapy, especially universal off-the-shelf products, represents a promising future direction in cancer treatment.
  • Continued research and technological innovation are crucial for optimizing allogenic CAR-T cell efficacy and safety.
  • The past decade has demonstrated substantial progress and success in applying allogenic CAR-T cells to hematological malignancies and cancers.